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ABSTRACT
Objective: To evaluate the cost-effectiveness of caspofungin
versus liposomal amphotericin B as empiric antifungal treat-
ment in patients with neutropenic fever in Italy.
Methods: The cost-effectiveness of caspofungin versus lipo-
somal amphotericin B was evaluated using a decision-tree
model. Patients were stratiﬁed by presence or absence of
baseline infection. Model outcomes included success in terms
of resolution of fever, resolution of baseline infection, absence
of breakthrough infection, survival, and quality-adjusted life
years (QALYs) saved. Discontinuation because of nephrotox-
icity or other adverse events were included in the model.
Efﬁcacy and safety data were based on a randomized, double-
blind, multinational trial of caspofungin compared to liposo-
mal amphotericin B (Walsh 2004). Information on life
expectancy, quality of life, medical resource consumption,
and costs was obtained from the literature.
Results: The caspofungin estimated total treatment cost
amounted to €8351 (95% uncertainty interval €7801–
€8903), which is €3470 (€2575–€4382) less than with
liposomal amphotericin B. Treatment with caspofungin
resulted in 0.25 (-0.11; 0.59) QALYs saved in comparison
to treatment with liposomal amphotericin B. Probabilistic
sensitivity analysis demonstrated a 93% probability that
caspofungin was economically dominant, i.e., cost and
QALY saving, and a probability of more than 99% that the
costs per QALY saved were below €20,000, a commonly
accepted threshold for cost-effectiveness. Additional analy-
ses with alternative doses of liposomal amphotericin B
conﬁrmed these ﬁndings.
Conclusion: Given the underlying assumptions, our eco-
nomic evaluation demonstrated that caspofungin is cost-
effective compared to liposomal amphotericin B in empiric
antifungal treatment of patients with neutropenic fever in
Italy.
Keywords: caspofungin, cost-effectiveness, empiric treat-
ment, fungal infections, Italy, liposomal amphotericin B.
Introduction
The incidence of invasive fungal infections has been
rising over the years [1]. The most common serious
fungal infections are disseminated candidiasis and pul-
monary aspergillosis. A major risk factor for invasive
fungal infection is prolonged neutropenia in patients
who receive chemotherapy for cancer or who undergo
hematopoietic stem-cell transplantation [2,3]. In
general (early) diagnosis of the fungal infection is dif-
ﬁcult and fever is the only sign of the fungal infection.
Consequently, empiric antifungal therapy is often ini-
tiated in neutropenic patients with persistent fever for
more than 5 days in addition to treatment with broad
spectrum antibiotics [4].
Amphotericin B (conventional or lipid-based for-
mulations, like liposomal amphotericin B [L-amB]) are
widely used in the treatment of neutropenic patients
with persistent fever [5]. Conventional amphotericin
B, however, is associated with nephrotoxicity which is
dose-limiting and a recognized driver of hospital costs
[6,7]. Lipid-based formulations of amphotericin are
increasingly being used in the treatment of neutropenic
fever, because they display less toxicity [8]. However, a
US study demonstrated that the high drug acquisition
costs of L-amB compared to conventional amphoteri-
cin B limits the economic value of L-amB [6]. Hospital
costs, from start of therapy to hospital discharge, were
estimated at about $49,000 and $43,000 for L-amB
and conventional amphotericin B, respectively, when
drug acquisition costs were included, but about
$40,000 versus $43,000, respectively, upon exclusion
of drug acquisition costs
Caspofungin, a relative new drug, is licensed for
empiric therapy of neutropenic fever. This license was
based on a randomized, double-blind, multinational
trial which assessed the efﬁcacy and safety of caspo-
fungin in comparison with L-amB as empiric therapy.
This trial showed that patients receiving caspofungin
experienced signiﬁcantly less nephrotoxicity (2.6%)
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and other drug-related events (5%) than patients
receiving L-amB (11.5% and 8%, respectively), while
maintaining comparable efﬁcacy [9].
Given the economic burden associated with empiric
treatment, formulary decision-making should be based
not only on efﬁcacy and safety of the available anti-
fungal agents but also on associated costs. Random-
ized controlled trials (RCTs), alone, often do not
provide sufﬁcient information for decisions related
to reimbursement or budget allocation, speciﬁcally if
medical resource consumption is not measured.
Model-based health economic studies are well
accepted for the assessment of the cost-effectiveness of
treatment. They allow the integration of efﬁcacy and
safety data from clinical trials and medical resource
consumption from other data sources. These models
also take into account the uncertainties that are
entailed in such a combination of information.
Recently, Bruynesteyn et al. [10] have used a model-
based economic evaluation in the UK and demon-
strated that caspofungin is cost-effective compared to
L-amB for empiric treatment of neutropenic patients
with persistent fever.
The objective of the current study was to evaluate
the cost-effectiveness of caspofungin relative to L-amB
for patients with persistent neutropenic fever in Italy
from the hospital perspective. The analysis was based
on a clinical trial of Walsh et al. [9]. In Italy, L-amB
and caspofungin are the only drugs licensed for
empiric treatment of persistent neutropenic fever [11].
Although conventional amphotericin B is accepted as
empiric treatment [11], a prospective European
observational study of which the majority of patients
received empiric treatment demonstrated that L-AmB
was the preferred formulation in Italy [12]. Conse-
quently, L-amB was chosen as the comparator
treatment.
Methods
Model Structure
A decision analytic model (Fig. 1) was developed to
estimate the cost-effectiveness of caspofungin (70 mg
on day one and 50 mg once daily thereafter) versus
L-amB (3 mg/kg per day for an average weight of
77 kg) for the treatment of a neutropenic patient with
persistent fever despite adequate antibacterial therapy
for 5 days. Based on the Walsh trial [9], the population
consisted of patients (56% male) with an average age
of 50 years and of which 74% suffered from acute
leukemia, 11% from non-Hodgkin lymphoma’s and
15% from other cancers. The model describes the costs
and outcomes of caspofungin and L-amB from start
of treatment to hospital discharge. Subsequently, the
treatment effects were translated to life years saved
given the life expectancy of patients that were still alive
at the end of the empiric treatment period.
The decision tree was designed to suit economic
analysis based on the Walsh trial [9]: mutually exclu-
sive categories of patients were identiﬁed to differen-
tiate between type of patients with varying degrees of
resource consumption, mortality, and success, which
are represented by the model branches (Fig. 1). This
approach reduced model complexity. A patient can
Success (P1)
No resolution of fever (P2)
Resolution of 
baseline infection
No resolution of 
baseline infection (P3)
Continue
Nephrotoxicity (P4)
Other adverse events (P5)
Discontinue
due to toxicity
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Success (P7)
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Death (P12)
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Figure 1 Decision-tree model for cost-effectiveness evaluation of caspofungin versus L-amb in the empiric treatment of fungal infections. L-amB,
liposomal amphotericin B.
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be deﬁned according to the presence (branches P1-P6
in Fig. 1) or absence of baseline infection (branches
P7-P12). A baseline infection was deﬁned as the pres-
ence of a proven or probable infection on the ﬁrst or
second day of the antifungal treatment [13]. Patients
that died on initial therapy were collapsed in two
branches (P6 and P12), irrespective of premature dis-
continuation of therapy or clinical failure, because
cause of death could not be ascertained from the
Walsh trial [9]. However, it is acknowledged that
these patients do not die instantaneously, but some-
where during the course of treatment before hospital
discharge. Consequently, costs and resource use were
considered for patients that died on initial therapy. A
patient that survived initial therapy (branches P1-P5
and P7-P11) could either continue their initial
therapy (P1-P3 and P7-P9) or discontinue because of
drug-related toxicity. Nephrotoxicity (P4 and P10), a
cost-driver, was differentiated from other drug-related
adverse events (P5 and P11).
A patient categorized as successful in branch P1
was deﬁned as having complete resolution of the
baseline fungal infection including resolution of their
fever during the neutropenic period, no premature
discontinuation of therapy because of drug-related
toxicity, and survival for 7 days after completion of
therapy. A patient categorized as successful in group
P7 (those without a baseline infection) had resolution
of fever during the neutropenic period and no break-
through fungal infection (= presence of infection from
day 3 onward) during therapy or within 3 days after
the completion of therapy, no premature discontinu-
ation of therapy because of drug-related toxicity, and
survival for 7 days after completion of therapy. If a
patient discontinued initial therapy, he or she was not
considered as successfully treated. These deﬁnitions
of success are in accordance with the ﬁve-component
end point used as primary efﬁcacy end point in
clinical trials on empiric antifungal treatments
[5,8,9,14,15].
If a patient discontinued initial therapy, a switch
to a second-line antifungal drug took place. It was
assumed that every patient that discontinued ﬁrst-line
caspofungin therapy switched to L-amB and that
every patient that discontinued L-amB therapy
switched to caspofungin. Mortality and costs of these
second-line antifungal drugs were also included in the
model.
For pragmatic reasons, it was assumed that a
patient does not discontinue because of lack of efﬁcacy.
Patients in the Walsh trial that discontinue because of
lack of efﬁcacy (5.4% and 5.6% for caspofungin and
L-amB, respectively) had either persistent fever or
suspected fungal infections [9] for which the model
accounted for in branches related to adverse clinical
outcomes (P3, P6, P9, P12).
Model outcomes by treatment arm included:
• Probability that the patient has a successful
outcome or dies on initial treatment;
• Expected antifungal drug costs (ﬁrst-line and
second-line), other direct costs (hospitalization
costs + drug costs, adverse events), and overall
costs.
Incremental outcomes included:
• Quality-adjusted life years (QALYs) saved: the dif-
ference in life years lost multiplied with the utility
(or quality of life score) based on the underlying
condition. QALY estimates were discounted at
3% per year according to Italian pharmacoeco-
nomic guidelines (2001);
• Cost difference;
• Cost per QALY saved.
Costs were expressed/updated to 2007 euros. It was
assumed hat the index ﬁgure of 2007 equals that of
2006 (http://www.istat.it).
The validation of the model and the elicitation of
consensus knowledge were obtained through an expert
meeting with four clinical experts led by one of the
coauthors (J.P.J.). For adaptations required for the
Italian situation Professor F. Aversa (coauthor) pro-
vided input.
Source Data
Efﬁcacy and discontinuation. The probabilities of sur-
vival, discontinuation of initial therapy, and effect of
treatment used in the model (see Table 1) were based
on the distribution of patients from the Walsh trial [9].
It was assumed that the presence of a proven baseline
infection did not inﬂuence the risk of discontinuation
of the ﬁrst-line treatment because of toxicity reasons.
Hence, the probabilities of discontinuation as used in
the model were based on the results of the entire trial
population in the RCT (and not stratiﬁed by baseline
infection).
The mortality during second-line treatment was
based on Maertens et al. [16]. This study evaluated the
efﬁcacy and safety of caspofungin in patients that were
refractory or intolerant to standard antifungal treat-
ment and showed that 24% (95% uncertainty range
0.15–0.33) of patients died during the treatment
period. In the model, this probability of dying was
applied to caspofungin (P4, P5) as well as L-amB (P10
and P11) branches.
QALYs saved: life expectancy and utility. The
expected life years lost per treatment arm were calcu-
lated by multiplying the probability of the branches
P6/P12 (death on ﬁrst-line treatment) and the mortal-
ity in branches P4-P5 and P10-P11 (death on second-
line treatment) with the life expectancy for the
underlying condition. For second-line treatment, the
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probability of dying was assumed to be 24% (15–
33%) [16]. An estimate of the life expectancy was
based on the underlying diagnoses. According to
Walsh et al. [9], 64% of the patients suffered from
acute myelogenous leukemia, 10% from acute lym-
phocytic leukemia, 11% from non-Hodgkin’s lym-
phoma, and 15% from other cancers. Based on 1, 3,
and 5 years’ survival data (1994–1999), which were
available from the Italian cancer registries participat-
ing in the EUROCARE-3 study [17], the life expect-
ancy was calculated assuming that survival followed a
Weibull distribution and a maximum possible age of
100 years. Fitting the Weibull distribution resulted in
an average discounted life expectancy of 8.4 years.
This estimate was assigned to branches P6 and P12 in
the model. Hence, the life years lost for second-line
treatment was 24% * 8.4 years = 2.0 years.
Each life year lost was valued with a utility value of
0.72 (0.50–0.94) in order to calculate the QALYs lost
when dying. This weighted utility value was extracted
from the catalog of preference scores 1997 from the
CEA Registry from Tufts New England Medical
Center (http://www.tufts-nemc.org) for the deﬁned
underlying conditions. According to the severity of
the underlying condition, the registry shows different
utilities, which were obtained by different methods.
This uncertainty in utility values was considered in the
analysis (see Analysis section). The low and high esti-
mates for leukemia (0.5–0.96) were based on chronic
leukemia with blast crisis versus survival without a
bone marrow transplant, respectively. The low and
high estimates for non-Hodgkin (0.57–0.92) were
based on non-Hodgkin treated with bone marrow
transplant and no remission versus remission after
2 years because of a chemotherapy regimen of cyclo-
phosphamide, hydroxydaunorubicin, oncovin, and
prednisone (CHOP), respectively. Low and high esti-
mates for the other cancer category (0.45–0.85) were
based on the preference weights for breast cancer (pro-
gressive breast cancer vs. complete response to chemo-
therapy for breast cancer, respectively). QALYs saved
were determined as the difference between QALYs lost
with caspofungin and L-amB.
Health-care utilization and cost. The direct medical
costs included were ﬁrst- and second-line antifungal
drug costs, costs because of adverse events, and the
cost of hospital stay—stratiﬁed by stay on the general
ward and stay in the intensive care unit (ICU).
Drug-related cost. To estimate the total cost of the
ﬁrst-line antifungal drug use, the average treatment
duration of the antifungal drug in the trial by Walsh
et al. (2004; data on ﬁle) was analyzed for each type of
patient included in the model (see Table 4). For the
model, it was assumed that the average treatment
duration was the same for the caspofungin and L-amB
treated patient.
The average treatment duration of the second-line
antifungal drug was assumed to be the same as the
treatment duration of a patient that continued initial
therapy. The total treatment duration for the patient
that discontinued and switched therapy was calculated
as the sum of average treatment duration of the
second-line drug and the average treatment duration of
the initial drug until discontinuation. Drug prices used
were based on published information from the Italian
Agency for Drugs. The price of caspofungin was
€510.28 for the ﬁrst day (70 mg) and €401.18 per day
(50 mg/day) from the second day onwards (Lista H,
published price). The price of L-amB (3 mg/kg per day)
was €685 per day (infomatore farmaceutico, a 50%
discount was applied on the net public price (10%
VAT) to reﬂect the hospital costs [18]).
Toxicity-related cost. Besides discontinuation because
of toxicity, the model also captured the impact of
drug-related toxicity (not leading to discontinuation)
on costs. Table 2 shows the adverse events other than
nephrotoxicity that occurred signiﬁcantly less often in
the caspofungin group compared to the L-amB group
[9] and were used in the model to calculate the
toxicity-related costs for each type of patient.
Table 1 Conditional probabilities of discontinuation and efﬁ-
cacy of ﬁrst-line treatment as used in model
Caspofungin L-amB
Baseline infection 0.05 (0.03–0.07) 0.05 (0.03–0.07)
Survival* 0.93 (0.85–1.00) 0.66 (0.37–0.74)
Continuation of initial antifungal
drug*
0.96 (0.94–0.97) 0.91 (0.89–0.94)
Resolution of baseline infection* 0.56 (0.37–0.75) 0.36 (0.11–0.61)
Discontinuation because of
toxicity*
0.04 (0.03–0.06) 0.09 (0.06–0.11)
Success (P1)* 0.29 (0.05–0.52) 0.40 (0.00–0.80)
Resolution of baseline infection,
no resolution of fever (P2)*
0.71 (0.48–0.95) 0.60 (0.20–1.00)
No resolution of baseline
infection (P3)*
0.44 (0.25–0.63) 0.64 (0.39–0.89)
Discontinuation because of
nephrotoxicity (P4)*
0.05 (0.00–0.09) 0.22 (0.09–0.35)
Discontinuation because of other
adverse events (P5)*
0.95 (0.91–1.00) 0.78 (0.65–0.91)
Death (P6)* 0.07(0.00–0.15) 0.44 (0.26–0.63)
No baseline infection 0.95 (0.93–0.97) 0.95 (0.93–0.97)
Survival* 0.93 (0.90–0.95) 0.91 (0.89–0.93)
Continuation of initial antifungal
drug*
0.96 (0.94–0.97) 0.91 (0.89–0.94)
Discontinuation because of
toxicity
0.04 (0.03–0.06) 0.09 (0.06–0.11)
Success (P7)* 0.41 (0.37–0.46) 0.42 (0.38–0.47)
No resolution of fever (P8)* 0.55 (0.50–0.59) 0.54 (0.50–0.59)
Breakthrough infection (P9)* 0.04 (0.02–0.06) 0.03 (0.02–0.05)
Discontinuation because of
nephrotoxicity (P10)*
0.05 (0.00–0.09) 0.22 (0.09–0.35)
Discontinuation because of other
adverse events (P11)*
0.95 (0.91–1.00) 0.78 (0.65–0.91)
Death (P12)* 0.07(0.05–0.10) 0.09 (0.07–0.11)
*Conditional probabilities (probability given the knowledge that the event in the
previous branch has occurred) with uncertainty ranges used for sensitivity analysis.
CEA of Caspofungin versus L-amB in Italy 833
A summated cost for chills, nausea, vomiting,
dyspnea, and ﬂushing was based on the drug(s) used for
these events (expert opinion). Oxygen was considered
the treatment of choice in the general ward for the
adverse event dyspnea. No detailed cost was available
for oxygen use. Because it can be considered a small
expense, associated cost was assumed to be included in
the cost because of length of stay (LOS) in a general
ward.
The probabilities of nephrotoxicity were based on
the additional analysis of the RCTbyWalsh et al. (2004
data on ﬁle). In the trial, signiﬁcantly fewer patients
in the caspofungin group experienced nephrotoxicity
compared to the L-amB group: 2.6% versus 11.5%.
Nephrotoxicity was deﬁned as a doubling of the serum
creatinine level or, if the creatinine level was elevated at
enrollment, an increase of at least 1 mg per deciliter [9].
For themodel, the risk of toxicitywas assumed not to be
inﬂuenced by the presence of a proven baseline infec-
tion.Hence, the probabilities of nephrotoxicity or other
adverse events in the model were based on the results of
the entire trial population. In Table 3, the probabilities
of nephrotoxicity for each type of patient in the model
are reported. For the patient that switched to a second-
line drug in the model (P4-P5 and P10-P11), the risk of
nephrotoxicity for the second-line drug was based on
the average probability of nephrotoxicity seen in the
ﬁrst-line treatments: 0.03 (0.01–0.04) for a patient that
switched to caspofungin and 0.12 (0.09–0.14) for a
patient that switched to L-amB. Treatment ranges from
suspension of all potentially and effectively nephrotoxic
drugs to, control of electrolyte imbalance, particularly
hyperkalemia, acidosis, and so on. Hemoﬁltration is
the last option when criteria for dialysis are fulﬁlled,
according to the consultant nephrologists. In themodel,
the probability of ICU stay (hemoﬁltration) in patients
with nephrotoxicity ranged according to treatment
branch from 2% (P1, P7) to 5% (P6 and P12) (expert
opinion). The cost estimate of hemoﬁltration was
obtained from a cost analysis of blood puriﬁcation in
ICUs by Vitale et al. [19].
LOS. In Italy, a patient without serious side effects
is usually immediately discharged after stopping the
antifungal therapy (expert opinion). Patients with
serious side effects because of the antifungal treat-
ment, however, stay much longer. The study by
Cagnoni et al. [20] showed that, in the USA, patients
with nephrotoxicity because of antifungal treatment
stayed on average 23 days in the hospital after starting
antifungal therapy although the average antifungal
treatment duration was 11 days. Hence, the LOS in the
hospital was 2.1 times longer than their actual treat-
ment duration. For Italy, this ﬁgure was considered too
high. Experts estimated that a ratio of about 1.5 seems
more appropriate. The average stay on the ICUs was
separately estimated and subtracted from the overall
LOS in the hospital in order to calculate the LOS in the
general ward.
LOS treatment duration LOSgeneral ward ICU= ∗( ) −1 5.
The average LOS in the ICU of patients with neph-
rotoxicity and a baseline infection was estimated at
0.73 extra days and 0.47 extra days in absence of a
baseline infection. The average LOS in the ICU for a
patient without nephrotoxicity and a baseline infection
was estimated at 0.32 extra days, and 0.16 extra days
in absence of a baseline infection. In Table 4, an over-
view of the used LOS in the general ward in the model
for different types of patients is presented. The per
diem cost for stay in general ward was €193 [21] and
the per diem cost for stay in the ICU was conserva-
tively estimated at €305, based on a study by Vitale
et al. which estimated the costs of an optimized
Table 2 Probability of an adverse event (other than nephrotoxicity) on ﬁrst-line treatment, and corresponding unit cost
Caspofungin L-amB Cost per event Source for costs
Chills 0.14 (0.11–0.17)* 0.25 (0.21–0.28) €20.3 (16.4–24.4) per event† Lista A,H,C
Nausea 0.04 (0.02–0.05) 0.11 (0.09–0.14) €39.2 (31.0–47.4) per event‡ Lista A,H,C
Vomiting 0.04 (0.02–0.05) 0.09 (0.06–0.11)
Dyspnoea 0.02 (0.01–0.03) 0.04 (0.03–0.06) 0
Flushing 0.02 (0.01–0.03) 0.04 (0.03–0.06) €3.8 (3.0–4.6) per event§ Lista A,H,C
*Uncertainty interval used for sensitivity analysis.
†Based on average use of paracetamol (i.v. and p.o.).
‡Nausea and vomiting, based on average use of metoclopramide and ondansetron (all i.v. and p.o.).
§Based on average use of chlorphenamine (i.v. and p.o.).
L-amB, liposomal amphotericin B.
Table 3 Probability of nephrotoxicity on ﬁrst-line treatment by
type of patient as used in model
Caspofungin L-amB
Type of patient:
Success (P1, P7) 0.01 (0.00–0.02)* 0.10 (0.06–0.15)
No resolution of fever (P2, P8) 0.02 (0.00–0.04) 0.07 (0.04–0.10)
No resolution of baseline
infection/breakthrough
infection (P3, P9)
0.07 (0.00–0.14) 0.33 (0.09–0.57)
Discontinuation because of
nephrotoxicity (P4)
1.00 (1.00–1.00) 1.00 (1.00–1.00)
Discontinuation because of
other adverse events (P5)
0.00 (0.00–0.00) 0.03 (0.00–0.06)
Death (P6) 0.12 (0.02–0.22) 0.21 (0.10–0.31)
*Uncertainty interval used for sensitivity analysis.
L-amB, liposomal amphotericin B.
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program for hemoﬁltration [19]. The unit cost esti-
mates included average drug costs and average proce-
dure costs (e.g., lab costs).
Analysis
The model allowed the calculation of outcomes for
both the caspofungin and the L-amB arm. The source
data (i.e., probabilities of discontinuation, efﬁcacy,
toxicity, treatment duration, and LOS) are character-
ized by uncertainty. In order to incorporate uncertainty
in the evaluation, a probabilistic sensitivity analysis
(PSA) was performed (Excel [2003]/Visual Basic) to
quantify the uncertainty in the model outcomes based
on the uncertainty of the input parameters. A random
value was sampled from distributions reﬂecting the
uncertainty of the input parameters. This random
sample was plugged in the model, and the correspond-
ing costs and effectiveness were calculated within the
model. This procedure was repeated 1000 times to
obtain uncertainty distributions of the outcomes. The
distributions of the input parameters were described
by beta distributions for the probabilities and utilities.
Normal distributions were used for the parameters
expressing LOS or duration of treatment. Negative
values were not sampled given the uncertainty range
used. Each outcome was presented with a point esti-
mate along with the uncertainty reﬂected by the 2.5th
percentile and 97.5th percentile of the uncertainty
distribution.
Uncertainty in cost per QALY saved was presented
as joint distributions on a cost-effectiveness plane and
with acceptability curves. In the acceptability curve,
the willingness to pay (WTP) per QALY saved was set
out on the horizontal axis against the probability that
caspofungin is cost-effective on the vertical axis. The
probability that caspofungin is cost-effective is based
on 1000 model simulations from the PSA. For each
WTP estimate, the number of simulation that caspo-
fungin is cost-effective out of the 1000 simulations was
calculated, as a measure of the probability.
In addition to the base-case scenario, as outlined
above, the following additional scenario analyses were
performed for Caspofungin versus L-amB:
• Costs based on 1 mg/kg dose of L-amB instead of
3 mg/kg.
• Costs based on 5 mg/kg dose of L-amB instead of
3 mg/kg.
• Length of stay calculated with the ratio LOS/
treatment duration of 2.1 (uncertainty range 1.7–
2.5) as reported by Cagnoni et al. [6].
Furthermore, one additional analysis was con-
ducted to compare caspofungin with amphotericin B
lipid complex (ABLC).
Results
Base-Case Scenario
As presented in Table 5, analysis of the model shows
that patients treated with caspofungin or L-amB for
Table 4 Treatment duration and additional length of stay (LOS) in the hospital because of empiric treatment of fungal infection by type
of patient
Duration initial
treatment
Duration
second-line
treatment
LOS general ward
With
nephrotoxicity
Without
nephrotoxicity
Patient with baseline infection
Patient continued initial therapy and was successfully treated (P1) 22.0 (13.5–30.5) — 32.3 (16.0–48.7) 23.9 (15.5–32.3)
Patient continued initial therapy, with resolution of baseline infection
but no resolution of fever (P2)
22.5 (15.3–29.7) — 32.9 (18.0–47.8) 24.3 (17.2–31.3)
Patient continued initial therapy, without resolution of baseline
infection (P3)
16.5 (8.2–24.8) — 24.0 (9.7–38.3) 18.2 (10.1–26.3)
Patient discontinued initial therapy because of nephrotoxicity (P4) 13.6 (1.0–26.3) 19.3 (11.4–27.3) 48.8 (14.8–82.7) —
Patient discontinued initial therapy because of other adverse events (P5) 13.6 (1.0–26.2) 19.3 (11.4–27.3) 49.0 (14.8–83.2) 34.8 (14.4–55.2)
Patient died during initial therapy (P6) 8.9 (6.8–11.0) — 12.7 (7.9–17.4) 10.4 (8.5–12.2)
Patient without baseline infection
Patient continued initial therapy and was successfully treated (P7) 15.7 (14.8–16.6) — 23.1 (7.5–28.7) 17.6 (16.7–18.5)
Patient continued initial therapy, without resolution of fever (P8) 10.7 (9.9–11.5) — 15.6 (11.8–19.5) 12.6 (11.9–13.3)
Patient continued initial therapy, with a breakthrough infection (P9) 19.9 (13.0–26.8) — 29.0 (15.3–42.6) 21.6 (14.9–28.3)
Patient discontinued initial therapy because of nephrotoxicity (P10) 12.2 (5.5–18.9) 13.1 (12.1–14.2) 37.3 (20.9–53.7) —
Patient discontinued initial therapy due to other adverse events (P11) 5.7 (4.2–7.2) 13.1 (12.1–14.2) 28.1 (19.4–36.7) 20.7 (18.2–23.3)
Patient died during initial therapy (P12) 11.2 (8.9–13.5) — 16.0 (10.3–21.6) 12.5 (10.5–14.5)
Table 5 Outcome results per treatment arm
Caspofungin
estimate
(p2.5–p97.5)*
L-amB
estimate
(p2.5–p97.5)
Probability of success 0.35 (0.32–0.38) 0.34 (0.31–0.37)
Probability of failure 0.57 (0.54–0.60) 0.55 (0.52–0.59)
Mortality during initial
treatment
0.07 (0.05–0.10) 0.11 (0.08–0.13)
Life years lost 0.70 (0.52–0.89) 1.05 (0.84–1.29)
QALYs lost 0.50 (0.31–0.70) 0.75 (0.47–1.03)
*Uncertainty range (2.5th percentile and 97.5th percentile of simulated uncertainty
distribution).
L-amB, liposomal amphotericin B; QALYs, quality-adjusted life years.
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neutropenic fever had comparable chances of ex-
periencing a successful outcome, i.e., about 35%.
Although the probability of an unsuccessful outcome
was comparable for the two interventions, the mortal-
ity among caspofungin treated patients was lower than
that for a patient treated with L-amB; 7% versus 11%.
When mortality on second-line treatment was also
incorporated and the total mortality was expressed in
number of life years lost relative to the life expectancy
of the underlying condition, treatment with caspofun-
gin is expected to save 0.35 life years (95% uncertainty
interval: 0.06–0.65) per patient compared to L-amB.
When quality of life is taken into consideration,
empiric treatment with caspofungin is expected to save
0.25 additional QALYs (95% uncertainty interval:
-0.11–0.59).
In Table 6 the direct cost per patient is presented for
both caspofungin and L-amB. The total direct costs
with caspofungin were lower than with L-amB, a dif-
ference of €3470 (€2575–€4382).
Figure 2 demonstrates the cost-effectiveness plane
of caspofungin compared to L-amb given the uncer-
tainty of the data inputs. Given the uncertainty in
estimated QALYs and costs saved with caspofungin,
there is a 93% probability that caspofungin is eco-
nomically dominant, i.e., more efﬁcacious and cost-
saving. When the decision-maker is willing to pay
for a QALY saved, the probability that caspofungin
is cost-effective compared to L-amB always exceeded
98%. The probability of an incremental cost-
effectiveness ratio below the accepted threshold of
€20,000–€30,000 per QALY saved was above 98%.
Alternative Scenarios
Caspofungin versus L-amB. If, in additional scenario
analysis, L-amB 1 mg/kg instead of 3 mg/kg was used,
the incremental direct cost for caspofungin relative to
L-amB would increase to +€2023 (€1227–€2860). The
resulting cost per QALY saved would be €7972 corre-
sponding to an 80% probability that caspofungin
would be cost-effective given the ceiling ratio of
€20,000 per QALY saved. If L-amB 5 mg/kg instead of
3 mg/kg was used, the incremental cost for caspofun-
gin was -€8937 (-€10,085 to -€7762). When the ratio
between LOS and duration of treatment was con-
sidered to be 2:1, in line with Cagnoni et al. [20],
instead of 1.5:1, the incremental costs were estimated
at -€3607 (-€2699 to -€4545) and a corresponding
probability of being cost-effective was >98% com-
pared to L-amB for a WTP of €20,000 per QALY
saved.
Table 6 Direct cost per treated patient in euro
Caspofungin
€ (p2.5–p97.5)*
L-amB
€ (p2.5–p97.5)
Estimated total
direct cost
8,351 (7,801–8,903) 11,821 (11,168–12,494)
Estimated antifungal
drug cost
5,684 (5,415–5,963) 8,999 (8,622–9,410)
Estimated other
direct cost
2,668 (2,234–3,120) 2,822 (2,348–3,311)
*Cost in euro; uncertainty range (2.5th percentile and 97.5th percentile of simulated
uncertainty distribution).
L-amB, liposomal amphotericin B.
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Figure 2 Cost-effectiveness plane: incremental cost and QALY saved for caspofungin versus L-amb. QALY, quality-adjusted life year.
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Caspofungin versus ABLC. In an additional analysis,
caspofungin was compared to ABLC (5 mg/kg), which
is an alternative lipid formulation of amphotericin B.
In the absence of RCTs comparing caspofungin with
ABLC, it was assumed that ABLC displayed an efﬁcacy
and safety equivalent to L-amB (3 mg/kg/day).
Figure 3 demonstrates the cost-effectiveness plane of
caspofungin compared to ABLC assuming equal efﬁ-
cacy and safety, but different drug costs. Clearly the
price difference between the two lipid formulations of
amphotericin B (L-amB is about two times more
expensive than ABLC: €332, Lista H, published price)
has its effect on the cost-effectiveness compared to
caspofungin. When the decision-maker is willing to
pay €20,000 per QALY saved, there is a 90% prob-
ability that caspofungin is cost-effective compared to
ABLC (see Fig. 4).
Discussion
The current evaluation compared the cost-effectiveness
of caspofungin relative to L-amB (3 mg/kg) for the
treatment of patients with persistent neutropenic fever
in Italy. Caspofungin and L-amB are the only antifun-
gal drugs that are licensed for empiric use in febrile
neutropenia in Italy. Although because of the broad
experience conventional amphotericin is accepted as
empiric treatment [11], a prospective observational
study of which the majority of patients received
empiric treatment demonstrated that L-AmB was the
preferred formulation of amphotericin in Italy [12].
The model demonstrated that caspofungin was eco-
nomically superior to L-amB: there is a 93% probabil-
ity that caspofungin is economically dominant over
L-amB, i.e., both QALYs and costs will be saved when
patients are treated with caspofungin. Other scenario
analyses, e.g. dosage of L-amB 5 mg/kg or a longer
hospital stay relative to the treatment duration did not
alter the conclusions. Even when compared to ABLC
(5 mg/kg), which is about half of the price of caspo-
fungin, there was a 90% probability for caspofungin
being cost-effective assuming a WTP of €20,000 per
QALY.
According to the 2002 guidelines of the Infectious
Disease Society of America, which are also applied in
Italy [11], addition of antifungal drugs is one of three
treatment options if fever persists after 5 days of anti-
biotic therapy and reassessment does not yield a cause
[4]. The two alternative treatment options at this stage
are: 1) continue antibiotics or 2) change or add anti-
biotics. From the guidelines, it follows that the type
and the prognosis of patients involved in the decision
for each option is clearly different. In order to incor-
porate patients that were comparable in terms of risk
at the decision of treatment, the current model consid-
ered the decision for the type of antifungal drug, and
did not include an extra branch where antifungals
were withheld.
The economic model was based on a clinical trial of
Walsh et al. [9], which included patients from more
than 100 centers and is considered to reﬂect a broad
population of patients in North America as well as
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Europe, and therefore applicable to Italy. In order to
develop an economic model for the antifungal treat-
ment of persistent neutropenic fever several simpliﬁca-
tions and assumptions were made with respect to
actual routine practice. First, the decision tree was
not designed to support decision-making in routine
practice, but structured to differentiate between type
of patients with varying degrees of resource consump-
tion, mortality, and success. For example, the ﬁrst
branch differentiated patients with a baseline infection
from those without, whereas in routine practice the
presence of baseline infection is not known at time of
treatment initiation (i.e., treatment of suspected fungal
infections). Second, the implications of assigning life
years lost to a patient who has died while receiving
empiric antifungal treatment for neutropenic fever
implies that no difference in life expectancy is assumed
for a patient that is successfully treated or that is a
failure. Because the probability of success (in absence
of fever) and failure was comparable for caspofungin
and L-amB, this will most likely not have inﬂuenced
the differences in estimated life years lost (and esti-
mated QALY lost) between the compared interven-
tions. A third simpliﬁcation was that the cost
consequences of absence of resolution of fever or of
breakthrough infection were not considered. Only a
small percentage of patients are in P3 and P9 branches:
1.8% and 3.2% for caspofungin and 1.6% and 2.6%
for L-Amb, respectively. Because these probabilities are
small and similar, ignoring these cost consequences
does not bias the estimate of the difference in overall
costs of caspofungin relative to L-amB.
Fourth, quality of life (or utility) during the neutro-
penic period when empirically treated for the fungal
infection was not taken into consideration in the
QALY calculations because of lack of information
available in the literature. However, the average
number of life years after the neutropenic period is
much larger than the weeks in a neutropenic state. For
the same reason, the utility associated with the termi-
nal phase of disease was not taken into account. There-
fore, QALY estimates are almost completely driven by
the utility of the life years after the neutropenic period.
Additionally, a simpliﬁcation was that a discontinuing
patient had a full course of the second-line therapy.
Because the probability of discontinuation was less
than 10%, this assumption will most likely not have
biased the cost estimates.
Although a model never perfectly reﬂects reality, we
believe that the conservative approach with regard to
the choice of assumptions underlying the model under-
line the credibility of the results and conclusions. For
example, the mortality rate of 24% assumed for
second-line treatment is based on the caspofungin
refractory aspergillosis study [16] where many patients
died 1–2 days after therapy was stopped. A higher
mortality rate, which would have been observed with
an extended time horizon, during second-line treat-
ment, would have further favored caspofungin as more
patients on L-amb discontinued and were on second-
line therapy. Also, assuming second-line mortality to
be equal for caspofungin and L-amB can be considered
a conservative estimate for caspofungin given the
mortality difference in ﬁrst-line treatment (Table 5).
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Furthermore, the current model utilizes a deﬁnition of
success which can be considered as quite conservative:
resolution of fever during the neutropenic period, no
premature discontinuation of therapy because of
drug-related toxicity and survival for 7 days after com-
pletion of therapy, and given the status at baseline
resolution of baseline infection or absence of break-
through infection as well. This deﬁnition of success
might underestimate the true effectiveness of the anti-
fungal drug, because it is well known that patients
adequately treated for their fungus can have fever
during their neutropenic period for a variety of other
reasons [3,22]. In an additional analysis of the Walsh
study data with alternate deﬁnitions of success
(eliminating fever resolution as a component of the
endpoint), caspofungin’s effectiveness was found to be
superior to L-amb [23]. Eliminating fever resolution
from the deﬁnition of success in the current model,
thereby combining branches P1 and P2 and branches
P7 and P8 showed that caspofungin was more efﬁca-
cious (84% [81–86%] probability of success) than
L-amB (77% [74–81%] probability of success), and
therefore economically dominant over L-amB: lower
costs and superior efﬁcacy.
Also, for the scenario analysis which compared
caspofungin and ABLC, the assumption of ABLC
(5 mg/kg) being equal to L-amb (3 mg/kg) with respect
to efﬁcacy and safety can be considered conservative.
One large RCT demonstrated, in patients empirically
treated for fungal infections, that L-amB (3 and 5 mg/
kg) displayed superior safety compared to ABLC
(5 mg/kg) [24]. Nephrotoxicity (based on the increase
in serum creatinine) as well as toxicity induced drug
discontinuation was signiﬁcantly higher in the ABLC
arm than in the L-amB arm. Furthermore, a retrospec-
tive analysis suggested that L-amB (3 mg/kg/day) is
more potent than ABLC: similar clinical outcomes
with a lower dose [25]. Other comparative studies
were not considered, because these have been per-
formed in small number of patients using historical
controls or included mixed populations of patients
[26–28] and were judged as inconclusive. With regard
to the scenario analysis of lower (1 mg/kg) and higher
doses of L-amB (5 mg/kg), in the absence of data, we
assumed that efﬁcacy and safety was similar to L-amB
(3 mg/kg) and only varied costs.
In the current analysis, we used the published price
for these hospital drugs. It is important to note that in
tenders manufacturers can provide additional dis-
counts of up to about 15% to drugs prescribed within
the hospital setting [18]. Although, these discounts
inﬂuence treatment costs, it may not impact relative
differences between L-amB and caspofungin. There-
fore, the conclusions with regard to the incremental
cost-effectiveness, dominance, and probability that
caspofungin is cost-effective given a WTP level should
not be affected by these discounts.
The results of the current analysis are restricted to
a patient with a weight of 77 kg which was chosen
similar to the UK situation [10]. It could be argued
that some empirically treated patients are often well
into several courses chemotherapy and weigh less.
However, adjusting the patient weight to 60 kg still
demonstrated that caspofungin was dominant.
In the current evaluation, the efﬁcacy and safety
information is obtained from a randomized double-
blind clinical trial. Although such a design provides a
high quality of evidence on the efﬁcacy and safety of
caspofungin relative to L-amB, the actual estimates
are characterized by (sampling) uncertainty (as repre-
sented by 95% conﬁdence intervals). Utility and
resource use data used in the evaluation were partly
extracted from the literature and partly from expert
opinion by which additional uncertainty is brought
into the picture. Model-based economic evaluations
only provide value if the uncertainties are made
explicit and their impact is investigated. Consequently,
a PSA was conducted to obtain a distribution of model
outcomes in terms of costs and effectiveness, with
some outcomes more likely than others. For the
current evaluation, it appeared that, despite the uncer-
tainty in input data, it is highly likely (more than 98%)
that caspofungin is cost-effective relative to L-amB, or
even economically dominant (93% probability).
From a cost-effectiveness standpoint, the primary
disadvantages of L-amB relative to caspofungin are the
higher drug acquisition costs, the higher probability of
nephrotoxicity and related discontinuation, and the
higher mortality given a baseline infection. Other eco-
nomic analysis also identiﬁed the drug acquisition
costs and nephrotoxicity as the drivers of the cost
difference between caspofungin and L-amB for empiric
antifungal therapy [10,29]. Nephrotoxicity results in
higher medical costs because of an increased LOS
including stay in ICU and hemoﬁltration. Discontinu-
ation of initial treatment and switch to second-line
therapy results in increased overall duration of the
antifungal therapy and LOS, with negative conse-
quences for the costs as well. The higher mortality with
L-amB resulted in more lost QALYs thereby compro-
mising its cost-effectiveness from the effectiveness side.
An additional drawback of nephrotoxicity is the delay
of a next cycle of chemotherapy, with possible conse-
quences regarding disease progression and survival of
the patient.
For this speciﬁc patient population and
treatment—empiric treatment of neutropenic
fever—only two other model-based economic evalua-
tions comparing caspofungin and L-amB have been
reported [10,29]. Both evaluations, one for the UK and
one for the USA, were based on the Walsh trial. The
UK-based analysis which used the same model struc-
ture as the current study resulted in a difference in total
treatment cost of £2033 in favor of caspofungin and
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considered caspofungin as a cost-effective treatment
[10]. These results are highly comparable to those for
the Italian setting. A US focused evaluation only
looked at the success rate of caspofungin and L-amB,
which is similar, and discarded the reported differences
in mortality [29]. Consequently, this study emphasized
the differences in costs and can be considered a cost
minimization analysis which is therefore different from
the current analysis. However, the estimated difference
in treatment costs of US$5326 in favor of caspofungin
is in line with those for the Italian setting. The external
validity of the evaluations is limited to the speciﬁc
patient population of the Walsh trial, not to patients
that received a solid organ transplant and those requir-
ing rifampin, cyclosporine or concomitant systemic
antifungal therapy which the trial excluded.
In conclusion, given the underlying assumptions
and data used, caspofungin can be considered a cost-
effective therapy for empiric treatment of fungal infec-
tions in neutropenic patients in Italy. Replacement of
L-amB with caspofungin is anticipated to have both
budgetary and health beneﬁts.
Source of ﬁnancial support: This study was funded by Merck
& Co., Inc.
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